NCT00866502View on ClinicalTrials.gov

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

sNN0031

Continuous ICV infusion for two weeks

DRUG

Placebo

Continous ICV infusion

Trial Locations (2)

22185

Lund University Hospital, Lund

141 86

Karolinska University Hospital, Huddinge, Stockholm

Sponsors

Collaborators (1)

Medtronic
All Listed Sponsors
collaborator

Medtronic

INDUSTRY

collaborator

Quintiles, Inc.

INDUSTRY

lead

Newron Sweden AB

INDUSTRY

NCT00866502 - A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter